A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ArQule
ClinicalTrials.gov Identifier:
NCT00558207
First received: November 12, 2007
Last updated: February 21, 2013
Last verified: February 2013
  Purpose

This is a multi-center, open-label randomized phase 2 study designed to assess the progression free survival (PFS) of patients with untreatment and unresectable pancreatic cancer following treatment with either ARQ 197 or gemcitabine. The study will also evaluate other efficacy and safety endpoints including overall response rate, overall survival and adverse events in the two treatment arms.


Condition Intervention Phase
Pancreatic Neoplasms
Drug: ARQ 197
Drug: gemcitabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by ArQule:

Primary Outcome Measures:
  • Evaluate progression-free survival (PFS) in patients receiving ARQ 197 versus gemcitabine. [ Time Frame: 6 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate overall response rate (ORR) in patients receiving ARQ 197 versus gemcitabine [ Time Frame: ongoing ] [ Designated as safety issue: No ]
  • Evaluate 6-month and 1-year overall survival (OS) rates in patients treated with ARQ197 versus gemcitabine [ Time Frame: 6 and 12 month ] [ Designated as safety issue: No ]
  • Further characterize the safety profile of ARQ 197 [ Time Frame: ongoing ] [ Designated as safety issue: No ]

Enrollment: 43
Study Start Date: November 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
ARQ 197
Drug: ARQ 197
120 mg capsule administered twice daily for 240 mg total daily dose
Active Comparator: 2
Gemcitabine
Drug: gemcitabine
1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
Other Name: Gemzar

Detailed Description:

This is a multi-center, open-label randomized phase 2 study designed to evaluate the PFS of treatment-naïve patients with unresectable (locally advanced or metastatic) pancreatic adenocarcinoma following treatment with either ARQ 197 (ARQ arm) or gemcitabine alone (GEM arm). The study will also evaluate other efficacy and safety parameters including ORR, OS and adverse events in the two treatment arms. Patients randomly assigned to the GEM arm will receive gemcitabine alone. Patients assigned to the ARQ arm will receive oral ARQ 197 alone.

ARQ 197 is an investigational oral drug supplied as capsules in multiple strengths. For the study initial shipment the capsules were 120 mg each, 30 count. In the ARQ arm, patients will take 120 mg of ARQ 197 twice daily, once in the morning and once in the evening one hour prior to or two hours after a meal. ARQ 197 treatment will be continued until unacceptable toxicity, documented progression of disease, or another discontinuation criterion is met.

Gemcitabine is a commercially available drug for the treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. In the GEM arm, gemcitabine will be administered by intravenous infusion over 30 minutes at a dose of 1000 mg/m2. The dosing schedule of gemcitabine will be once weekly for the first cycle (4 weeks), then once weekly for 3 consecutive weeks followed by a week of rest for each subsequent cycle. Gemcitabine therapy will be continued until unacceptable toxicity, documented progression of disease, or another discontinuation criterion is met.

A treatment cycle is defined as 28 days for both treatment arms. Cycles may be repeated every 4 weeks (28 days) based on toxicity and response. The assigned treatment should continue until unacceptable toxicity, disease progression (clinical or radiological) or another discontinuation criterion is met.

Tumor evaluations: Tumor evaluations will be performed in 8-week intervals. Tumor response (complete response, partial response, stable disease, progressive disease and ORR) will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).

Progression-free survival: The time of disease progression-free will be calculated from randomization until disease progression per RECIST or death due to any cause. Patients who are alive and progression free will be censored at the date of their last tumor evaluation.

Overall survival: Overall survival time will be calculated from the date of randomization until death due to any cause.

Safety assessments: Data on vital signs, physical examination, adverse events, serum chemistry, hematological laboratory tests, and electrocardiograms will be collected.

This study is designed to establish potential efficacy of ARQ 197 in treatment naive pancreatic cancer patients in a controlled, randomized study. The sample size of 30 Evaluable patients per treatment group is considered adequate to provide meaningful estimates of the PFS and ORR and OS rates, however, this study is not powered to show statistically significant differences between the treatment groups. Therefore, the analyses will be primarily descriptive in nature. Taking into account an anticipated drop-out/loss-to-follow-up rate of 20%, the total sample size will be 72 patients.

Primary and secondary objectives will be analyzed in the two treatment arms using appropriate patient populations and statistical methods.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able to provide signed and dated informed consent prior to study-specific screening procedures
  2. ≥ 18 years old
  3. Histologically or cytologically confirmed locally advanced or metastatic unresectable pancreatic adenocarcinoma
  4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
  5. Karnofsky performance status (KPS) ≥ 70%
  6. Male or female patients of child-producing potential must agree to use double barrier contraception, oral contraceptives or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment
  7. Females of childbearing potential must have a negative serum pregnancy test
  8. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN with metastatic liver disease
  9. Hemoglobin ≥ 10 g/dl
  10. Total bilirubin ≤ 1.5 × ULN
  11. Serum creatinine ≤ 1.5 x ULN
  12. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
  13. Platelets ≥ 100 x 10^9/L

Exclusion Criteria:

  1. Received any prior therapy for the treatment of their pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational)
  2. Central nervous system metastases
  3. Pregnant or breastfeeding
  4. Significant gastrointestinal disorder, in the opinion of the Principal Investigator (e.g. Crohn's disease, ulcerative colitis, extensive gastric resection)
  5. Unable or unwilling to swallow ARQ 197 capsules twice daily
  6. Other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
  7. Significant co-morbid conditions that in the opinion of the Investigator would impair study participation
  8. Known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00558207

Locations
Poland
Oddzial Chemioterapii, Wojewodzki Szpital Specjalistyczny
Krakow, Poland, 31-826
Oddzial Kliniczny Kliniki Onkologii Szpital Uniwersytecki w Krakowie
Krakow, Poland, 31-531
Oddział Onkologii Klinicznej, Regionalny Szpital Specjalistyczny "Latawiec"
Swidnica, Poland, 58-100
Oddział Onkologii Klinicznej SP ZOZ Wojewódzki Szpital Zespolony im. L. Rydygiera
Torun, Poland, 53/59
Klinika Onkologii WIM Warszawa
Warszawa, Poland, 00-909
Oddział Chemioterapii Dolnośląskie Centrum Onkologii
Wroclaw, Poland, 53-413
Sponsors and Collaborators
ArQule
Investigators
Principal Investigator: Cezary Szczylik, PhD Klinika Onkologii WIM
Principal Investigator: Janusz Pawlega, PhD Oddzial Kliniczny Kliniki Onkologii
Principal Investigator: Piotr Koralewski, MD Oddzial Chemioterapii Krakow
Principal Investigator: Emilia Filipczyk-Cisarz, MD Oddzial Chemioterapii Dolnoslaskie Centrum Onkologii
Principal Investigator: Ewa Kilar, MD Regionalny Szpital Specjalistyczny Latawiec
Principal Investigator: Piotr Sawrycki, MD Oddzial Onkologii Klinicznej im L Rydygiera
  More Information

No publications provided

Responsible Party: ArQule
ClinicalTrials.gov Identifier: NCT00558207     History of Changes
Other Study ID Numbers: ARQ 197-205
Study First Received: November 12, 2007
Last Updated: February 21, 2013
Health Authority: United States: Food and Drug Administration
Poland: Ministry of Health

Keywords provided by ArQule:
Pancreatic cancer
pancreas cancer
Locally advanced or metastatic pancreatic adenocarcioma

Additional relevant MeSH terms:
Adenocarcinoma
Neoplasms
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on April 17, 2014